Combination cancer therapies can shrink tumors and improve outcome in advanced non-small lung cancer: Clinical trial

While pembrolizumab is an approved treatment for patients with stage III non-small cell lung cancer (NSCLC), only some patients respond to this therapy. Treatment failure, researchers say, is often caused by differences in the tumor microenvironment.

Leave A Comment

Your email address will not be published. Required fields are marked *